Free Trial

GENFIT (GNFT) Competitors

GENFIT logo
$3.97 +0.19 (+4.92%)
Closing price 07/23/2025 03:53 PM Eastern
Extended Trading
$3.97 +0.01 (+0.20%)
As of 07/23/2025 04:26 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

GNFT vs. AVBP, VIR, IOVA, AMLX, SION, CRMD, TNGX, IMTX, STOK, and URGN

Should you be buying GENFIT stock or one of its competitors? The main competitors of GENFIT include ArriVent BioPharma (AVBP), Vir Biotechnology (VIR), Iovance Biotherapeutics (IOVA), Amylyx Pharmaceuticals (AMLX), Sionna Therapeutics (SION), CorMedix (CRMD), Tango Therapeutics (TNGX), Immatics (IMTX), Stoke Therapeutics (STOK), and Urogen Pharma (URGN). These companies are all part of the "pharmaceutical products" industry.

GENFIT vs. Its Competitors

GENFIT (NASDAQ:GNFT) and ArriVent BioPharma (NASDAQ:AVBP) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, profitability, risk, analyst recommendations, media sentiment, institutional ownership, dividends and earnings.

In the previous week, ArriVent BioPharma had 9 more articles in the media than GENFIT. MarketBeat recorded 9 mentions for ArriVent BioPharma and 0 mentions for GENFIT. ArriVent BioPharma's average media sentiment score of 0.65 beat GENFIT's score of 0.00 indicating that ArriVent BioPharma is being referred to more favorably in the news media.

Company Overall Sentiment
GENFIT Neutral
ArriVent BioPharma Positive

GENFIT has higher revenue and earnings than ArriVent BioPharma.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GENFIT$76.77M2.58$1.63MN/AN/A
ArriVent BioPharmaN/AN/A-$80.49M-$3.77-5.81

GENFIT's return on equity of 0.00% beat ArriVent BioPharma's return on equity.

Company Net Margins Return on Equity Return on Assets
GENFITN/A N/A N/A
ArriVent BioPharma N/A -49.21%-46.61%

GENFIT presently has a consensus price target of $13.00, suggesting a potential upside of 227.79%. ArriVent BioPharma has a consensus price target of $39.29, suggesting a potential upside of 79.47%. Given GENFIT's higher probable upside, equities research analysts clearly believe GENFIT is more favorable than ArriVent BioPharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
GENFIT
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
ArriVent BioPharma
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
3.14

GENFIT has a beta of 1.08, suggesting that its share price is 8% more volatile than the S&P 500. Comparatively, ArriVent BioPharma has a beta of 1.2, suggesting that its share price is 20% more volatile than the S&P 500.

2.2% of GENFIT shares are held by institutional investors. Comparatively, 9.5% of ArriVent BioPharma shares are held by institutional investors. 4.2% of GENFIT shares are held by company insiders. Comparatively, 18.6% of ArriVent BioPharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

ArriVent BioPharma beats GENFIT on 8 of the 13 factors compared between the two stocks.

Get GENFIT News Delivered to You Automatically

Sign up to receive the latest news and ratings for GNFT and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GNFT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GNFT vs. The Competition

MetricGENFITMED IndustryMedical SectorNASDAQ Exchange
Market Cap$189.01M$2.99B$5.57B$9.42B
Dividend YieldN/A2.44%4.05%3.99%
P/E RatioN/A21.2528.1520.08
Price / Sales2.58253.33401.6884.07
Price / Cash54.0441.9636.1958.45
Price / Book2.648.198.625.83
Net Income$1.63M-$55.10M$3.24B$258.27M
7 Day Performance3.15%5.56%3.55%2.69%
1 Month Performance3.01%18.19%11.01%12.91%
1 Year Performance-6.24%7.32%35.56%21.81%

GENFIT Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GNFT
GENFIT
2.2908 of 5 stars
$3.97
+4.9%
$13.00
+227.8%
-5.7%$189.01M$76.77M0.00120Gap Up
AVBP
ArriVent BioPharma
2.27 of 5 stars
$21.55
-2.3%
$39.29
+82.3%
+7.1%$754.39MN/A-5.7240Analyst Forecast
Analyst Revision
VIR
Vir Biotechnology
3.691 of 5 stars
$5.52
+2.0%
$30.25
+448.0%
-42.6%$747.87M$74.21M-1.31580
IOVA
Iovance Biotherapeutics
4.6346 of 5 stars
$2.49
+11.7%
$12.22
+390.9%
-54.3%$744.67M$212.68M-2.01500Analyst Forecast
Options Volume
Gap Up
High Trading Volume
AMLX
Amylyx Pharmaceuticals
3.3162 of 5 stars
$8.21
-1.6%
$11.75
+43.1%
+328.1%$743.44M$87.37M-2.64200
SION
Sionna Therapeutics
N/A$17.44
+4.2%
$38.50
+120.8%
N/A$738.64MN/A0.0035
CRMD
CorMedix
2.8938 of 5 stars
$10.94
+0.7%
$17.14
+56.7%
+140.6%$736.58M$43.47M49.7330
TNGX
Tango Therapeutics
1.3529 of 5 stars
$6.77
flat
$10.50
+55.1%
-29.4%$733.83M$42.07M-5.5590Gap Up
IMTX
Immatics
3.0863 of 5 stars
$5.85
-2.5%
$14.67
+150.7%
-50.1%$729.30M$168.65M-34.41260News Coverage
Positive News
STOK
Stoke Therapeutics
4.2718 of 5 stars
$12.31
-6.9%
$25.80
+109.6%
-2.1%$721.77M$36.56M15.58100Gap Up
URGN
Urogen Pharma
4.5083 of 5 stars
$15.46
+1.2%
$32.86
+112.5%
+10.2%$705.49M$91.87M-4.86200High Trading Volume

Related Companies and Tools


This page (NASDAQ:GNFT) was last updated on 7/24/2025 by MarketBeat.com Staff
From Our Partners